We are live on ! Find out more
PTC

Philadelphia Trust Company Portfolio holdings

AUM $1.42B
1-Year Est. Return 43.77%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+43.77%
3 Year Est. Return
+141.5%
5 Year Est. Return
+176.17%
10 Year Est. Return
+554.31%
AUM
$1.13B
AUM Growth
+$197M
Cap. Flow
+$32.7M
Cap. Flow %
2.88%
Top 10 Hldgs %
29.71%
Holding
207
New
31
Increased
81
Reduced
51
Closed
7

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$13.7M
2
MDT icon
Medtronic
MDT
+$11.2M
3
TER icon
Teradyne
TER
+$8.87M
4
KSS icon
Kohl's
KSS
+$7.5M
5
ROK icon
Rockwell Automation
ROK
+$6.74M

Sector Composition

Rank Sector Weight
1 Technology 21.45%
2 Financials 17.16%
3 Healthcare 15.07%
4 Communication Services 11.69%
5 Industrials 9.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DVY icon
201
iShares Select Dividend ETF
DVY
$23.6B
-3,232
Closed -$289K
HUN icon
202
Huntsman Corp
HUN
$1.77B
-254,870
Closed -$4.92M
RACE icon
203
Ferrari
RACE
$72.5B
-12,786
Closed -$1.27M
SPIB icon
204
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.5B
-8,261
Closed -$273K
TSN icon
205
Tyson Foods
TSN
$20.4B
-63,933
Closed -$3.41M

Similar funds

Philadelphia Trust Company's Q1 2019 Portfolio in Review

As of Q1 2019, Philadelphia Trust Company held 207 positions worth $1.13B, up 21% from $936M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Philadelphia Trust Company's Q1 2019 filing shows 31 new, 81 increased, 51 reduced and 7 closed positions. Its largest new stake was Teradyne: 237,280 shares worth $9.45M. The largest sale was REGENERX BIOPHARMACEUTICALS, an estimated $60.9M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.

  • Philadelphia Trust Company's largest Q1 2019 buy was Teradyne: 237,280 shares worth $9.45M.
  • Philadelphia Trust Company added most to Intel in Q1 2019, an estimated $13.7M increase.
  • Philadelphia Trust Company's biggest Q1 2019 reduction was REGENERX BIOPHARMACEUTICALS, cutting an estimated $60.9M.
  • Philadelphia Trust Company fully exited Huntsman Corp in Q1 2019, selling an estimated $4.92M.
  • Philadelphia Trust Company's ten largest holdings make up 30% of its $1.13B portfolio in Q1 2019.
  • Philadelphia Trust Company opened 31 new positions and closed 7 in Q1 2019.
  • Philadelphia Trust Company's portfolio value rose 21% quarter-over-quarter to $1.13B.

Based on Philadelphia Trust Company's 13F filing for Q1 2019, filed 15 May 2019.